Drugmaker Cipla has launched Afrezza (insulin human) inhalation powder, the company said, about a year after the product got regulatory approval in India. The company has the exclusive distribution and marketing rights of Afrezza, a rapid-acting orally-inhaled insulin, which offers a needle-free alternative to injectable insulin therapy, it said, without disclosing its pricing. Afrezza from US’ MannKind Corporation dissolves rapidly upon oral inhalation and begins lowering blood glucose within approximately ...